The CDSCO is India’s top drug regulator. Since 2023, the Indian government has been working on the ‘Jan Vishwas Act’ to decriminalize minor offenses in various sectors, including pharmaceuticals, to help businesses operate without the fear of criminal cases for small mistakes.

The Drugs and Cosmetics Act, 1940, is the primary law regulating the pharmaceutical industry in India. Historically, even small errors like paperwork mistakes could lead to criminal cases, which many argued was too harsh for minor technical faults.

In the legal world, ‘litigation’ means fighting a case in court, which can take years. ‘Compounding’ is a faster alternative where the offender pays a fine to the regulator to close the case immediately. The ‘regulator’ here is the CDSCO, which has the power to decide which cases can be settled this way.

The Jan Vishwas (Amendment of Provisions) Act, 2023, amended 42 Central Acts across various sectors. Its main goal was to reduce the compliance burden on individuals and businesses by replacing criminal imprisonment with monetary penalties for minor, technical, or procedural defaults.

Section 32B was added to the 1940 Act to allow ‘compounding’ (settling cases with fines). Section 27(a-c) covers very serious crimes like manufacturing fake (spurious) or dangerous (adulterated) drugs, which can lead to life imprisonment. The Jan Vishwas Act ensures that only minor violations—not these serious crimes—can be settled through fines.

In legal terms, ‘immunity from prosecution’ means the government agrees not to charge you with a crime or take you to trial for a specific act. In this case, once a company pays the compounding fine, the CDSCO will not pursue a criminal case in court for that particular violation.

A law is only as good as how it is applied. The editorial suggests that while the new rules are good on paper, they will only be successful if the CDSCO uses them honestly to help genuine businesses, rather than letting dishonest companies escape punishment.

The pharmaceutical industry involves a lot of paperwork (record keeping). Errors in this paperwork are often technical and don’t harm patients directly. By settling these with fines, the government can use its limited resources to catch serious criminals who make fake or dangerous medicines (direr violations).

The editorial highlights two big worries: 1) Companies might treat fines as just a ‘cost of doing business’ and keep making mistakes (pay and pass). 2) If the CDSCO doesn’t share details of who was fined and why, the public won’t know if the regulator is being fair or if some companies are getting special treatment.

The law allows companies to settle their mistakes at any stage. They can do it as soon as the mistake is found (before prosecution) to avoid going to court at all, or they can even do it while the trial is going on (after prosecution) to end the case early.

Transparency is key to public trust. If the government settles cases behind closed doors without telling the public what happened, people might think that rich companies are simply paying bribes or using influence to avoid real punishment.

An ‘auditable trail’ means that every step of the process—from the application to the final fine—is recorded. If these records are public, independent groups can check if the CDSCO is actually stopping repeat offenders from using the system, as the law requires.

The editorial argues that we shouldn’t just trust the CDSCO to follow its own rules. ‘Independent actors’ like health activists or consumer groups need to see the data to verify that the regulator isn’t letting the same company settle its crimes over and over again, which would be against the law.

Whistle-blowers are often the only ones who know about hidden crimes inside a company. The editorial criticizes the new rules for not giving these people or consumer groups a chance to speak up and stop a company from getting a ‘clean chit’ (immunity) if they have evidence of more serious wrongdoing.

When a law is written in a ‘broad’ way, it gives the government a lot of power to interpret it. The editorial warns that if the definition of ‘minor errors’ is too broad, companies might try to settle serious safety violations (substantive failures) by calling them simple ‘paperwork mistakes’ (lapses).

The goal of any law is to make sure people follow it (compliance). If the punishment is too small, companies might find it cheaper to pay the fine than to follow the rules. This means the law loses its power to scare people into being honest (deterrence).

In the pharmaceutical industry, ‘CAPA’ (Corrective and Preventive Action) is a standard process to fix errors and ensure they don’t happen again. A ‘product recall’ is when a company takes back all the medicine from the market because it is found to be unsafe. The editorial says that just paying a fine isn’t enough; companies must also fix their systems and warn the public if needed.

The ultimate goal of drug regulation is to keep patients safe. The editorial concludes that if the government only focuses on collecting fines (compounding) without making sure companies fix their underlying problems, the danger to the public will remain the same in the long run.